The factor XI inhibitor is manufactured by Isis Pharmaceuticals. “This study really shows for the first time that if you target factor XI, you can push venous thrombosis rates down to 4 percent, which has never been done before,” said study author Harry R. Büller, MD, PhD, according to the report.
The study compared the use of the factor XI inhibitor with enoxaparin.
Read the full study here.
More articles on orthopedics:
Invuity names Paul Davison, Doug Heigel to senior leadership
5 things to know about contralateral ACL reconstruction
Dr. Aaron Dickens joins Great Basin Orthopaedics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.